KyNexis B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
KyNexis B.V. - overview
Established
2023
Location
Naarden, -, Netherlands
Primary Industry
Pharmaceuticals
About
Based in Naarden, Netherlands, and 2023, KyNexis B. V. operates as a biotechnology company that offers therapeutic solutions to improve brain function, particularly cognitive impairment associated with schizophrenia. In November 2023, KyNexis B.
V. raised EUR 57 million in series A funding led by Forbion, with participation from another Ysios Capital Partners and Sunstone Life Science Ventures. Kynexis is a biotechnology company developing precision therapeutics for brain diseases, with a focus on cognitive impairment associated with schizophrenia (CIAS). They are taking a biomarker-based approach to identify patients most likely to benefit from their potential new therapy, which targets KAT-II, a key enzyme in the kynurenine pathway.
Kynexis is led by an accomplished team of industry experts, and they are committed to transforming the treatment paradigm of schizophrenia.
Current Investors
Forbion, Ysios Capital Partners, Sunstone Life Science Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.kynexistx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
KyNexis B.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.